Enterprise value to revenue forward of Protagonist Therapeutics, Inc. – NASDAQ:PTGX
The article provides the enterprise value to revenue forward for Protagonist Therapeutics, Inc. (NASDAQ: PTGX). It presents basic financial and market information for the company as listed on TradingView, covering its Nasdaq Stock Market data.
Protagonist Therapeutics Inc stock hits all-time high at 131.99 USD
Protagonist Therapeutics Inc. (PTGX) stock has reached an all-time high of $131.99, currently trading at $132.27, showcasing a significant 163.93% increase over the past year. Despite analysts viewing the stock as overvalued, they predict profitability this year with forecasted earnings of $5.01 per share, driven by positive developments and investor confidence. Several analysts have reiterated "Outperform" or "Buy" ratings, citing commercial launches, anticipated approvals, and a strong pipeline, with the company holding $620 million in cash.
Price to book forward of Protagonist Therapeutics, Inc. – NASDAQ:PTGX
This article displays the "Price to book forward" financial metric for Protagonist Therapeutics, Inc. (NASDAQ: PTGX) on TradingView. It indicates the period, value, and change of this data point. The page structure includes typical TradingView financial data presentation, despite the core content being minimal.
PTGX - Protagonist Therapeutics Inc Volatility & Greeks
This article provides a detailed financial overview of Protagonist Therapeutics Inc. (PTGX), including its recent stock performance, key financial metrics, volatility data, and important dates such as IPO and earnings reports. It also lists insider and institutional ownership, analyst recommendations, and various technical indicators, offering a comprehensive snapshot of the company's market position.
Protagonist Therapeutics updates its pipeline. PTGX focuses on peptide drug development
Protagonist Therapeutics (PTGX) is a clinical-stage biopharmaceutical company advancing its pipeline of peptide-based medicines for immune and inflammatory diseases. The company focuses on targeted treatments designed to modulate specific pathways, aiming for precise and potentially safer options. Protagonist Therapeutics' strategy involves concentrating resources on lead candidates, with stock performance closely tied to pipeline progress and clinical data readouts.
Why Wall Street’s Wrong for Loving Protagonist Therapeutics Stock
The author, Jim Van Meerten, argues that Wall Street analysts are incorrect in their bullish sentiment towards Protagonist Therapeutics (PTGX). Despite the stock's strong technical momentum and high buy signals, he advises caution due to its low price stability, high short interest, erratic earnings predictions, high valuation, and low growth, opting to invest elsewhere. He notes that while analysts have target prices up to $137, other sources like Morningstar and Seeking Alpha rate it as overvalued or a "Hold."
Protagonist Therapeutics stock rating reiterated at Buy by TD Cowen
TD Cowen has reiterated a Buy rating for Protagonist Therapeutics (NASDAQ:PTGX), maintaining a $100 price target. The stock has seen a significant 144% gain over the past year, currently trading near its 52-week high, although InvestingPro analysis suggests it may be overvalued. The company anticipates data from its PN-881 trial in Q3, with expectations for direct advancement to a psoriasis Phase IIb trial and potential profitability this year.
PTGX - Protagonist Therapeutics Inc Latest SEC Filings
This article provides the latest SEC filings and comprehensive financial data for Protagonist Therapeutics Inc (PTGX). It includes key financial metrics such as market cap, income, sales, EPS, and various ratios, along with stock performance metrics, insider ownership, and institutional transactions. The data reflects the company's financial health, recent stock performance, and trading activity.
Protagonist Therapeutics Reports Granting of Inducement Awards
Protagonist Therapeutics announced granting inducement awards to three new employees on June 30, 2026, under their Amended and Restated Inducement Plan. These awards include options to purchase 8,050 shares and restricted stock units for 2,545 shares, with an exercise price of $122.50 per share, vesting over a four-year period. The company also highlighted its proprietary technology for peptide therapeutics and its pipeline candidates, including J&J-licensed JICOTRO™ and Takeda Pharmaceutical-licensed Rusfertide.
Protagonist Therapeutics Reports Granting of Inducement Awards
Protagonist Therapeutics, Inc. reported granting inducement awards to three new employees on June 30, 2026. These awards, consisting of stock options and restricted stock units, were part of their employment offers and approved by the company's compensation committee. The awards are structured with vesting schedules over four-year periods.
Protagonist Therapeutics awards new hires stock options and RSUs
Protagonist Therapeutics (Nasdaq: PTGX) granted inducement awards to three new employees on June 30, 2026, comprising options for 8,650 shares and 2,275 Restricted Stock Units (RSUs), with an exercise price of $122.58 per share. These awards, approved by the compensation committee, are intended to materially induce employment under Nasdaq Rule 5635(c)(4). The options vest over four years, while RSUs vest in four equal annual installments.
Protagonist Therapeutics stock rating reiterated at Buy by TD Cowen
TD Cowen has reiterated a Buy rating for Protagonist Therapeutics (NASDAQ:PTGX) with a $100 price target, noting the stock's significant 144% gain over the past year. The firm anticipates positive PN-881 data in Q3 and expects a robust launch for Rusfertide following its August PDUFA date. Other analysts from Wolfe Research, BMO Capital, Citizens, Jefferies, and Truist Securities have also issued positive ratings and price targets, highlighting the company's strong pipeline and commercial potential.
Protagonist Therapeutics stock rating reiterated at Buy by TD Cowen
TD Cowen has reiterated a Buy rating and a $100 price target for Protagonist Therapeutics (NASDAQ: PTGX), despite the stock currently trading above this target at $124.08, reflecting a 144% gain over the past year. The firm anticipates positive PN-881 data in Q3 and expects a robust launch for Rusfertide, pending August PDUFA approval. Analyst consensus remains strong on the company's growth potential and market opportunities, with several other firms also maintaining Outperform or Buy ratings.
Protagonist Therapeutics, Inc. Actuals & Estimates (NASDAQ:PTGX)
This article provides financial analysis and estimates for Protagonist Therapeutics, Inc. (NASDAQ: PTGX), detailing its stock performance, analyst forecasts, and historical financial data. It includes details on revenue, earnings, market capitalization, and upcoming earnings reports, along with frequently asked questions about the company's stock.
PTGX Forecast — Price Target — Prediction for 2027
This article provides a detailed forecast and financial overview for Protagonist Therapeutics, Inc. (PTGX). It includes analyst price targets, historical stock performance, earnings data, revenue figures, and other key financial and operational metrics. The information is presented in a Q&A format, addressing various aspects of the company's stock and financial health.
Form 144 PROTAGONIST THERAPEUTICS For: 23 June By Investing.com
This article reports on a Form 144 filing for PROTAGONIST THERAPEUTICS for June 23. Form 144 filings indicate an affiliate's intent to sell restricted securities. The article provides the title and publication details, noting it's from Investing.com.
The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following Surging Institutional Buying Interest
Protagonist Therapeutics (PTGX) is experiencing a surge in institutional buying interest, driven by stronger revenue, profit, and operating efficiency. While the core catalysts remain the Q3 2026 PDUFA for rusfertide and progress in other programs, this heightened institutional conviction, alongside improving financials, could amplify stock price sensitivity to future news despite existing risks like insider selling and high expectations. The article suggests that PTGX might still be undervalued, with fair value estimates significantly above its current price.
Form 144 PROTAGONIST THERAPEUTICS For: 23 June By Investing.com
This article announces the filing of Form 144 for Protagonist Therapeutics (PTGX) on June 23, 2026. Form 144 indicates an insider's intent to sell restricted securities, which can be of interest to investors tracking company stock movements. The filing details are provided by Investing.com, a financial markets news source.
PTGX (NASDAQ) Form 144: Director-linked 9,000-share sales and option exercise
A Form 144 filing for Protagonist Therapeutics, Inc. (PTGX) indicates a proposed sale of 9,000 shares on June 23, 2026, stemming from an exercise of stock options. The filing also details two prior 10b5-1 sales, each for 9,000 shares, executed on June 10, 2026, for $969,152.40 and on May 29, 2026, for $896,730.30, attributed to William D. Waddill. These procedural notices highlight insider dispositions and option exercises without indicating a negative or positive impact on the company.
The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following Surging Institutional Buying Interest
Protagonist Therapeutics (PTGX) is experiencing a surge in institutional interest, with major asset managers increasing their holdings due to improved revenue, profit, and operating efficiency. This, combined with positive technical indicators and high institutional ownership, suggests growing confidence in the biotech company. However, the core investment narrative still hinges on the Q3 2026 PDUFA for rusfertide and progress in other pipeline programs.
Protagonist Therapeutics Inc (PTGX) Financial Health: Profitability & Balance Sheet Analysis
Protagonist Therapeutics Inc (PTGX) has a robust financial status, scoring 7.93 out of 10 and ranking 75th in the Biotechnology & Medical Research industry. The company reported a significant year-over-year revenue increase of 99.03% to $56.37M and net profit growth of 132.46%. While specific detailed financial metrics are not yet disclosed by the company, its operational efficiency and growth potential are noted as high.
Protagonist Therapeutics stock hits all-time high at 113.75 USD
Protagonist Therapeutics' stock has reached an all-time high of $113.75, reflecting a 106.68% increase over the past year and a market capitalization of $7.17 billion. This surge is supported by positive analyst ratings from Wolfe Research, BMO Capital, Citizens, Jefferies, and Truist Securities, highlighting the company's promising pipeline and the success of Icotyde. Despite the positive momentum, InvestingPro suggests the stock may be overvalued at current levels.
Protagonist Therapeutics stock hits all-time high at 113.75 USD By Investing.com
Protagonist Therapeutics (PTGX) stock has reached an all-time high of $113.75, with a market capitalization of $7.17 billion, reflecting a significant 106.68% surge over the past year. Despite analysts highlighting its innovative pipeline and commercial potential with several "outperform" ratings and price target increases, InvestingPro analysis suggests the stock may be overvalued. The company reported $620 million in cash and equivalents as of March 31, 2026, with a projected financial runway through 2028.
Protagonist Therapeutics stock hits all-time high at 113.75 USD By Investing.com
Protagonist Therapeutics (PTGX) stock reached an all-time high of $113.75, pushing its market capitalization to $7.17 billion, reflecting a 106.68% increase over the past year. This surge is supported by positive analyst ratings from Wolfe Research, BMO Capital, Citizens, Jefferies, and Truist Securities, citing promising pipeline developments and the approval of Icotyde. Despite the growth, InvestingPro analysis suggests the stock might be overvalued at current levels.
Protagonist Therapeutics (PTGX) OKs 2026 equity plan and re-elects directors at annual meeting
Protagonist Therapeutics (PTGX) stockholders approved a new 2026 Equity Incentive Plan, re-elected two Class I directors, and ratified Ernst & Young LLP as their independent registered public accounting firm at the 2026 annual meeting. The new equity plan replaces the 2016 plan and allows for the issuance of additional shares and the re-granting of certain returning shares. Shareholders also approved, on an advisory basis, the compensation for named executive officers.
Protagonist Therapeutics stock hits all-time high at 113.75 USD By Investing.com
Protagonist Therapeutics Inc. (PTGX) stock has reached an all-time high of $113.75, reflecting a 106.68% surge over the past year and resulting in a market capitalization of $7.17 billion. Despite this strong performance, InvestingPro analysis suggests the stock is currently overvalued. Several analysts have initiated or reiterated positive ratings, citing the company's pipeline and successful approval of Icotyde for psoriasis.
Protagonist Therapeutics Inc (PTGX) Valuation: PE, PB & Fair Value Analysis
Protagonist Therapeutics Inc (PTGX) has a current valuation score of 9.48, placing it 31st out of 388 in the Biotechnology & Medical Research industry. Its P/E ratio is -61.77, which is notably below its recent high and slightly above its recent low. The company has not yet disclosed relevant data for P/B, P/S, and P/CF ratios.
Protagonist Therapeutics Inc (PTGX) Earnings Forecast: Future EPS & Revenue Growth Estimates
Protagonist Therapeutics Inc (PTGX) has an earnings forecast score of 8.57, ranking 99th in the Biotechnology & Medical Research industry, with an average price target of $91.00. Based on 14 analysts, the stock has a "Buy" rating. The expected revenue for the next quarter is $213.37 million, and the EPS for the next quarter is projected to be $1.94, compared to a previous quarter's EPS of -$0.69.
Protagonist Therapeutics Inc (PTGX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution — TradingKey
This article provides an overview of Protagonist Therapeutics Inc (PTGX), including its stock performance and market capitalization. It highlights that detailed revenue breakdown by business segments and regions has not yet been disclosed by the company. The content primarily focuses on financial data availability for PTGX on the TradingKey platform.
PTGX: All proposals, including director elections and equity plan, were approved at the AGM
At Protagonist Therapeutics, Inc.'s (PTGX) 2026 Annual General Meeting, all proposed agenda items were approved. These approvals included the election of directors, executive compensation, auditor ratification, and the equity incentive plan. The voting results for these proposals will be officially filed with the SEC.
Protagonist Therapeutics Reports Granting of Inducement Awards
Protagonist Therapeutics, Inc. reported granting inducement awards to three new employees on June 15, 2026, including options to purchase 14,800 shares and restricted stock units for 3,900 shares. These awards, approved by the compensation committee, serve as a material inducement for their employment in accordance with Nasdaq rules. The company is a biotechnology firm focused on peptide therapeutics with several drug candidates in development or near commercialization.
New hires at Protagonist receive stock options at $112.46
Protagonist Therapeutics (Nasdaq: PTGX) granted inducement equity awards to three new employees on June 15, 2026. The awards include 14,800 stock options at an exercise price of $112.46 and 3,900 Restricted Stock Units (RSUs), both with four-year vesting schedules. These grants were made under the company's Amended and Restated Inducement Plan and approved in accordance with Nasdaq Rule 5635(c)(4).
Protagonist Therapeutics Reports Granting of Inducement Awards
Protagonist Therapeutics (Nasdaq: PTGX) announced it granted inducement awards to three new employees on June 15, 2026, comprising options for 14,800 shares and RSUs for 3,900 shares of common stock. These awards, approved by the compensation committee, were a material inducement for their employment under Nasdaq Marketplace Rule 5635(c)(4). The company also highlighted its late-stage development pipeline, including ICOTYDE™ and rusfertide, both nearing commercialization, and other clinical programs.
Protagonist Therapeutics Reports Granting of Inducement Awards
Protagonist Therapeutics, Inc. announced that on June 15, 2026, it granted inducement awards to three new employees as per their employment offer letters. These awards, including options to purchase 14,800 shares and restricted stock units for 3,700 shares, were approved by the compensation committee of the Company's board of directors and are subject to a four-year vesting schedule. The inducement awards comply with Nasdaq Marketplace Rule 5635(c)(4).
Protagonist Therapeutics (PTGX) Stock Valuation After Strong Recent Returns And Premium P/B Multiple
Protagonist Therapeutics (PTGX) has seen strong recent returns, trading at US$109.78 with a 94.75% total shareholder return over the past year. While its P/B ratio of 10.8x is attractive compared to direct peers, it's significantly higher than the broader US biotech sector average, indicating high market expectations for its drug candidates. Despite this premium, a Discounted Cash Flow model suggests the stock could be trading 71.1% below an estimated fair value of $379.98.
Protagonist Therapeutics (PTGX) Stock Valuation After Strong Recent Returns And Premium P/B Multiple
Protagonist Therapeutics (PTGX) has experienced strong recent returns, with its stock closing at US$109.78 and showing significant gains over various periods. Despite trading at a premium Price-to-Book (P/B) ratio of 10.8x compared to the broader US biotech sector, this figure is below its direct peers, suggesting potential value. A Discounted Cash Flow (DCF) model by Simply Wall St indicates that PTGX could be trading 71.1% below an estimated fair value of $379.98.
NEXTBio Capital Management LP Takes Position in Protagonist Therapeutics, Inc. $PTGX
NEXTBio Capital Management LP recently acquired a new stake in Protagonist Therapeutics (NASDAQ:PTGX), purchasing 229,619 shares valued at approximately $20.1 million. This investment makes PTGX the second-largest holding for NEXTBio, representing 11.8% of its portfolio. Institutional ownership of Protagonist Therapeutics is notably high at 98.63%, with several major funds increasing their positions, and analysts generally hold a "Moderate Buy" rating for the stock.
Keystone Investors PTE Ltd. Buys Shares of 26,390 Protagonist Therapeutics, Inc. $PTGX
Keystone Investors PTE Ltd. initiated a new position in Protagonist Therapeutics (NASDAQ:PTGX) during the fourth quarter, acquiring 26,390 shares valued at approximately $2.3 million. This purchase contributes to highly concentrated institutional ownership, with major firms like Vanguard and UBS collectively holding 98.63% of the company's stock. Analysts generally maintain a "Moderate Buy" rating for Protagonist Therapeutics, with a consensus target price of $115.21, following a recent strong earnings beat.
Protagonist Therapeutics director Waddill sells $969,120 in shares
William D. Waddill, a director at Protagonist Therapeutics, sold 9,000 shares of the company's common stock for approximately $969,120 after exercising stock options. These transactions were pre-arranged under a 10b5-1 trading plan, and the stock is currently trading near its 52-week high, with analysts maintaining positive ratings and price targets. The company maintains a strong financial position with an expected operational runway through 2028.
Protagonist Therapeutics (NASDAQ: PTGX) director exercises 9,000 options, sells 9,000 shares under 10b5-1 plan
Protagonist Therapeutics director William D. Waddill exercised 9,000 stock options at strike prices of $16.54 and $11.80, then sold 9,000 shares in the open market at a weighted average price of $107.68. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026. After these activities, Waddill directly holds 7,825 shares of Protagonist Therapeutics common stock.
Transcript : Protagonist Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 09
This article provides the transcript of Protagonist Therapeutics, Inc.'s presentation at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. The presentation featured CEO Dinesh Patel. The full transcript of the event is reserved for subscribers.
571,825 Shares in Protagonist Therapeutics, Inc. $PTGX Bought by Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.
Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. has acquired a significant new position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX), purchasing 571,825 shares valued at approximately $49.9 million. This investment represents 4.4% of the firm's portfolio and 0.91% of Protagonist Therapeutics' outstanding shares. The purchase comes despite recent insider selling by executives, showcasing institutional confidence in the company which recently exceeded earnings and revenue estimates.
Protagonist Therapeutics stock hits all-time high at 107.86 USD By Investing.com
Protagonist Therapeutics (PTGX) stock has reached an all-time high of $107.86, trading just 1% below its 52-week high with a market capitalization of $6.76 billion and an 87.81% 1-year total return. This surge is attributed to promising pipeline developments and strategic partnerships, with several analysts initiating or reiterating outperform/buy ratings and increasing price targets due to the successful launch and potential of its product, Icotyde. Despite its strong performance, InvestingPro analysis indicates the stock is currently trading above its Fair Value and is listed among the most overvalued.
[144] Protagonist Therapeutics, Inc SEC Filing
A recently filed SEC Form 144 for Protagonist Therapeutics, Inc. (PTGX) indicates an insider's proposed sale of 9,000 shares under a 10b5-1 plan, generating $896,730.30, coupled with an option exercise for the same number of shares. The filing notes the 10b5-1 sale occurred on May 29, 2026, and the stock options were exercised on June 10, 2026, with a cash payment to the issuer. This activity, classified as neutral in sentiment, highlights pre-arranged insider trading, though specific financial details like strike price and net proceeds are not disclosed in the excerpt.
PTGX: Icotyde's strong launch and a robust pipeline drive growth, with Rusfertide approval expected soon
Protagonist Therapeutics, Inc. (PTGX) is highlighted as a growing commercial-stage biotech, driven by the successful launch of Icotyde and the anticipated approval of Rusfertide. The company also possesses a robust and de-risked pipeline, including innovative oral peptides for immunology, inflammation, and obesity, with future plans for strategic partnerships and shareholder rewards.
Protagonist Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Protagonist Therapeutics' CEO, Dinesh Patel, discussed the company's current positive position at the Goldman Sachs Healthcare Conference. He highlighted Protagonist as a commercial entity with ICOTYDE, partnered with J&J, and is anticipating potential FDA approval for rusfertide in Q3, partnered with Takeda. If approved, Protagonist Therapeutics will have two approved drugs this year.
Clearbridge Investments LLC Buys Shares of 489,842 Protagonist Therapeutics, Inc. $PTGX
Clearbridge Investments LLC has acquired a new stake in Protagonist Therapeutics (NASDAQ:PTGX), purchasing 489,842 shares valued at approximately $42.8 million. This comes as insider selling also occurred, with the CEO and a Director selling shares worth millions. Despite insider sales, Protagonist Therapeutics reported better-than-expected quarterly earnings and revenue, and analysts currently maintain a "Moderate Buy" rating with an average target price of $115.21.
Protagonist Therapeutics Jumps 6.3% Amid Sector-Wide Rally
Protagonist Therapeutics (PTGX) saw its stock jump 6.3% to $104.16 on Tuesday, as it participated in a broad rally across the biotechnology sector. The increase was attributed to sector-wide momentum rather than company-specific news, with other biotech peers also posting similar gains. Investors will be watching for Protagonist to sustain these levels with future company-specific developments.
BNP Paribas Financial Markets Has $8.54 Million Stock Holdings in Protagonist Therapeutics, Inc. $PTGX
BNP Paribas Financial Markets significantly increased its stake in Protagonist Therapeutics, Inc. (PTGX) by 632.6% in the fourth quarter, now holding 97,764 shares worth approximately $8.54 million. This comes after Protagonist Therapeutics reported better-than-expected Q1 earnings, with $0.05 EPS and $56.37 million in revenue. Despite a "Moderate Buy" consensus from analysts and an average price target of $115.21, there has been notable insider selling by the CEO and CFO.
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025
Protagonist Therapeutics announced that its President and CEO, Dinesh V. Patel, Ph.D., will participate in several investment bank conferences in September 2025. These include Citi's 2025 Biopharma Back to School Summit, H.C. Wainwright's 27th Annual Global Investment Conference, and BofA's 11th Annual World Medical Innovation Forum. The company will share updates on its advanced Phase 3 clinical developments for icotrokinra and rusfertide, with NDA submissions planned for both.
